Citigroup Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Neutral rating on Neurocrine Biosciences (NBIX) and raises the price target from $140 to $150.
May 03, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has maintained its Neutral rating on Neurocrine Biosciences but increased the price target from $140 to $150.
The increase in the price target by Citigroup suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential for both upward and downward movements.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90